Announcements Trials
Browse Landscape

Phase

Phase 1 25Phase 1/2 13Phase 2 10Phase 3 6Phase 2/3 2

Status

Completed 3Recruiting 2Active not recruiting 1

Sponsor Class

INDUSTRY 6OTHER 5NETWORK 3NIH 2OTHER_GOV 1

Study Type

Interventional 6

Sponsor

Cancer Type

Dermatologic 6

Conditions

Carcinoma, Non-Small-Cell Lung 437Breast Neoplasms 382Neoplasms 291Prostatic Neoplasms 195Neoplasm Metastasis 155Multiple Myeloma 148Colorectal Neoplasms 124Lung Neoplasms 105Ovarian Neoplasms 102Parkinson Disease 4, Autosomal Dominant Lewy Body 98Melanoma 95Lymphoma, Follicular 94Recurrence 89Lymphoma, Non-Hodgkin 82Papillomavirus Infections 81Leukemia, Lymphocytic, Chronic, B-Cell 81Carcinoma, Hepatocellular 81Stomach Neoplasms 76Small Cell Lung Carcinoma 73Leukemia, Myeloid, Acute 70Pancreatic Neoplasms 67Pain 66Carcinoma, Renal Cell 65Uterine Cervical Neoplasms 64Keratosis, Actinic 63Urinary Bladder Neoplasms 59Lymphoma, Large B-Cell, Diffuse 53Myasthenia Gravis 52Leiomyoma 49Carcinoma 49

Interventions

Melphalan 3Neoadjuvant Therapy 1Dacarbazine 1Chemotherapy, Cancer, Regional Perfusion 1AZD 6244 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Phase 3 × INDUSTRY × Uveal Melanoma × Clear all
NCT07015190 2026-05-06

Neoadjuvant Darovasertib in Primary Uveal Melanoma

IDEAYA Biosciences

Phase 3 Recruiting
520 enrolled
Dermatologic

Uveal Melanoma, Melanoma

NCT06007690 2026-03-02

CoMpass

Aura Biosciences

Phase 3 Recruiting
100 enrolled
Dermatologic

Uveal Melanoma, Eye Neoplasms

NCT02678572 2023-12-21

FOCUS

Delcath Systems Inc.

Phase 3 Completed
102 enrolled 1 FDA
Dermatologic

Uveal Melanoma

NCT05022901 2023-12-21

An Open-Label Expanded Access Study of the Melphalan/Hepatic Delivery System (HDS) in Patients With Hepatic Dominant Ocular Melanoma

Delcath Systems Inc.

Phase 3 Active not recruiting
30 enrolled
Dermatologic

Uveal Melanoma

NCT00324727 2021-06-21

Hepatic Arterial Infusion With Melphalan Compared With Standard Therapy in Treating Patients With Unresectable Liver Metastases Due to Melanoma

Delcath Systems Inc.

Phase 3 Completed
93 enrolled
Dermatologic

Uveal Melanoma, Melanoma, Neoplasm Metastasis

NCT01974752 2017-01-05

SUMIT

AstraZeneca

Phase 3 Completed
152 enrolled 14 charts
Dermatologic

Uveal Melanoma, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡